BioNTech SE (BNTX) Other Non-Current Assets (2018 - 2025)
BioNTech SE (BNTX) posted Other Non-Current Assets of $3.0 billion for Q4 2025, up 768.3% sequentially from $342.4 million in Q3 2025, and up 121.88% YoY from $1.3 billion in Q4 2024.
BioNTech SE (BNTX) Other Non-Current Assets (2018 - 2025) Analysis & Trends
BioNTech SE has reported Other Non-Current Assets for 6 years, with the latest figure at $3.0 billion in Q4 2025.
- Quarterly Other Non-Current Assets rose 121.88% year-over-year to $3.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 billion (up 121.88% YoY) and the FY2025 annual result came in at $2.9 billion, up 115.35% from the prior year.
- Other Non-Current Assets grew to $3.0 billion in Q4 2025 per BNTX's latest filing, from $342.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.0 billion in Q4 2025 and troughed at $129.7 million in Q4 2021.
- A 4-year average of $588.1 million and a median of $307.2 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Assets soared 10780.43% in 2021, then slumped 37.1% in 2025.
- Over 4 years, Other Non-Current Assets stood at $129.7 million in 2021, then surged by 140.16% to $311.6 million in 2023, then surged by 330.11% to $1.3 billion in 2024, then surged by 121.88% to $3.0 billion in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $3.0 billion, $342.4 million, and $243.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 202.31 Mn |
| Sep 30, 2025 | 342.42 Mn |
| Jun 30, 2025 | 243.37 Mn |
| Mar 31, 2025 | 246.46 Mn |
| Dec 31, 2024 | 227.29 Mn |
| Sep 30, 2024 | 302.89 Mn |
| Jun 30, 2024 | 386.93 Mn |
| Mar 31, 2024 | 366.10 Mn |
| Dec 31, 2023 | 302.23 Mn |
| Sep 30, 2023 | 311.55 Mn |
| Jun 30, 2023 | 231.18 Mn |
| Mar 31, 2023 | 183.86 Mn |
| Dec 31, 2021 | 129.73 Mn |
| Dec 31, 2020 | 1.19 Mn |
| Dec 31, 2018 | 20,545.14 |